These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24797897)

  • 1. Ramucirumab in metastatic renal cell carcinoma: the sex, race, and age issues.
    Liu F; Liu Q; Wang G; Gu W
    Cancer; 2014 Aug; 120(15):2379. PubMed ID: 24797897
    [No Abstract]   [Full Text] [Related]  

  • 2. Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?
    Pal SK; Figlin RA
    Cancer; 2014 Jun; 120(11):1604-7. PubMed ID: 24577887
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
    Garcia JA; Hudes GR; Choueiri TK; Stadler WM; Wood LS; Gurtler J; Bhatia S; Joshi A; Hozak RR; Xu Y; Schwartz JD; Thompson JA
    Cancer; 2014 Jun; 120(11):1647-55. PubMed ID: 24577874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor.
    Mizuno R; Miyajima A; Oya M
    Int J Urol; 2014 Jul; 21(7):740. PubMed ID: 24673489
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug treatment of metastatic renal cell carcinoma].
    Rafiyan MR; Jäger E
    Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1567-70. PubMed ID: 23836159
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiogenetic pathway as a therapeutic target in renal cell carcinoma.
    Bianconi M; Scartozzi M; Faloppi L; Bittoni A; Maccaroni E; Giampieri R; Del Prete M; Burattini L; Cascinu S
    Anal Quant Cytol Histol; 2012 Feb; 34(1):15-22. PubMed ID: 22590815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the role of MET kinase in cancer therapy.
    Posadas EM; Figlin RA
    J Clin Oncol; 2013 Jan; 31(2):169-70. PubMed ID: 23213104
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment to activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor.
    Wada Y
    Int J Urol; 2014 Jul; 21(7):741. PubMed ID: 24761966
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
    Reuter CW; Morgan MA; Grünwald V; Herrmann TR; Burchardt M; Ganser A
    World J Urol; 2007 Mar; 25(1):59-72. PubMed ID: 17340158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
    J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
    De Pasquale MD; Pessolano R; Boldrini R; Ilari I; Donfrancesco A; Cortesi E; Jenkner A
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):e176-9. PubMed ID: 21552143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
    Schrader AJ; Varga Z; Pfoertner S; Goelden U; Buer J; Hofmann R
    BJU Int; 2006 Mar; 97(3):461-5. PubMed ID: 16469008
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 18. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase inhibitors in the treatment of renal cell carcinoma.
    Larkin JM; Eisen T
    Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment approaches in metastatic renal cell carcinoma.
    Mancuso A; Sternberg CN
    Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.